President Trump’s intervention came while Mr. Milton was appealing his conviction on securities and wire fraud charges.
Category: Securities and Commodities Violations
-
S.E.C. Declares Memecoins Are Not Subject to Oversight
The agency said the novelty digital assets were not securities, a month after President Trump issued his own memecoin.
-
Nikola, E.V. Start-Up That Once Thrilled Investors, Files for Bankruptcy
The company, which once enjoyed a surging stock price, struggled to turn its plans for electric and hydrogen trucks into a viable business.
-
S.E.C. Moves to Scale Back Its Crypto Enforcement Efforts
Some in a special unit of 50 lawyers and staff members that had been assigned to regulate cryptocurrency are being reassigned in the agency.
-
Vanguard to Pay $106 Million in Restitution to Retirement Fund Investors
An investigation by the S.E.C. and several states found that the company had failed to notify investors of changes in the terms of some funds, leading to higher capital gains taxes.
-
Robinhood to Pay $45 Million Fine to Settle SEC Charges
The upstart brokerage agreed to pay the Securities and Exchange Commission for failing to protect sensitive customer data, among other infractions.
-
Former MoviePass Executive Pleads Guilty to Fraud Over ‘Unlimited’ Plan
Prosecutors said that Theodore Farnsworth, who ran the parent company of MoviePass, had misled investors about its popular subscription plan.
-
Elon Musk and DOGE vs. Regulators
The billionaire has needled government agencies, armed with potential influence over their budgets. But some of these organizations are also looking into his interests.
-
Supreme Court Won’t Decide Nvidia Securities Fraud Case After All
In an unsigned order, the justices dismissed the case against the tech giant as “improvidently granted,” meaning they had concluded that it had been a mistake to take it up.
-
Trump Picks Paul Atkins to Run the S.E.C.
Mr. Atkins, a pro-business conservative, would likely take a lighter regulatory approach than the current chair of the Securities and Exchange Commission.
-
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.